

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
6 January 2017**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Arbutus Biopharma Corporation**

**File No. 1-34949 -- CF# 34403**

---

Arbutus Biopharma Corporation submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 3, 2016, as amended on December 22, 2016.

Based on representations by Arbutus Biopharma Corporation that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

|              |                         |
|--------------|-------------------------|
| Exhibit 10.1 | through August 9, 2026  |
| Exhibit 10.2 | through October 7, 2026 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary